Related Experiment Video
Updated: Apr 23, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
17.3K
Angiotensin receptor blockers for heart failure
Phillip Jong1, Catherine Demers2, Robert S McKelvie3
1University of Toronto, Toronto, Canada.
The Cochrane Database of Systematic Reviews
|October 1, 2014
Summary
Angiotensin II Receptor Blockers (ARBs) efficacy in heart failure patients is under investigation. This review compares ARBs against placebo or ACEIs for survival and hospitalization rates.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Heart failure (HF) is a significant cause of morbidity and mortality.
- Current treatments, including Angiotensin-Converting Enzyme Inhibitors (ACEIs), have limitations.
- Angiotensin II Receptor Blockers (ARBs) offer an alternative therapeutic pathway.
Purpose of the Study:
- To evaluate the efficacy of ARBs in improving survival rates for heart failure patients.
- To assess the impact of ARBs on heart failure hospitalization rates.
- To compare ARBs directly with placebo and ACEIs in heart failure management.
Main Methods:
- Systematic review and meta-analysis protocol.
- Inclusion of randomized controlled trials comparing ARBs with placebo or ACEIs.
- Focus on patient survival and hospitalization as primary outcomes.
Main Results:
- Data synthesis to determine the comparative effectiveness of ARBs.
- Statistical analysis to quantify differences in mortality and hospitalization.
- Identification of potential benefits and risks associated with ARB therapy.
Conclusions:
- Evidence synthesis on ARBs for heart failure management.
- Informing clinical guidelines for heart failure treatment.
- Highlighting the role of ARBs in relation to established therapies like ACEIs.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
01:22Heart Failure Drugs: β-Blockers
2.3K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.3K
01:30Heart Failure V: Medical Management
606
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
606
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.8K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.8K
01:22Heart Failure Drugs: Diuretics
1.3K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.3K